ELF2

Summary

ELF2 (E74 like ETS transcription factor 2, HGNC:3317) is a protein-coding gene on chromosome 4q31.1, encoding ETS-related transcription factor Elf-2 (Q15723). Isoform 1 transcriptionally activates the LYN and BLK promoters and acts synergistically with RUNX1 to transactivate the BLK promoter.

Enables DNA-binding transcription factor activity, RNA polymerase II-specific and sequence-specific double-stranded DNA binding activity. Involved in negative regulation of DNA-templated transcription; positive regulation of DNA-templated transcription; and regulation of transcription by RNA polymerase II. Located in cytosol and nuclear body.

Source: NCBI Gene 1998 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 87 total — 1 likely-pathogenic
• Transcription factor: yes — 12 downstream targets (CollecTRI)
• MANE Select transcript: NM_001331036

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3317
Approved symbol	ELF2
Name	E74 like ETS transcription factor 2
Location	4q31.1
Locus type	gene with protein product
Status	Approved
Aliases	EU32, NERF, NERF-2, NERF-1A, NERF-1B
Ensembl gene	ENSG00000109381
Ensembl biotype	protein_coding
OMIM	619798
Entrez	1998

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 10 protein_coding, 4 retained_intron, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000358635, ENST00000379549, ENST00000379550, ENST00000394235, ENST00000504314, ENST00000510408, ENST00000511006, ENST00000511184, ENST00000512627, ENST00000514577, ENST00000514606, ENST00000515489, ENST00000686138, ENST00000864104, ENST00000864105, ENST00000935561

RefSeq mRNA: 11 — MANE Select: NM_001331036 NM_001276457, NM_001276458, NM_001276459, NM_001331036, NM_001371324, NM_001371336, NM_001371337, NM_001371338, NM_001371339, NM_006874, NM_201999

CCDS: CCDS3744, CCDS3745, CCDS64062, CCDS64063, CCDS82954

Canonical transcript exons

ENST00000686138 — 10 exons

Exon	Start	End
ENSE00000739091	139060324	139060674
ENSE00000970367	139125164	139125329
ENSE00001192730	139137630	139137867
ENSE00001403285	139071866	139072039
ENSE00001517815	139139413	139139497
ENSE00001517816	139176967	139177218
ENSE00001744714	139061865	139062057
ENSE00003582840	139073454	139073567
ENSE00003653488	139067684	139067770
ENSE00003932468	139057265	139059607

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 97.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.0719 / max 579.2423, expressed in 1807 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
54050	11.5191	1725
54046	5.9945	1635
54045	4.5582	1537

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	97.19	gold quality
colonic epithelium	UBERON:0000397	94.64	gold quality
cortical plate	UBERON:0005343	94.60	gold quality
adrenal tissue	UBERON:0018303	93.88	gold quality
ganglionic eminence	UBERON:0004023	93.48	gold quality
ventricular zone	UBERON:0003053	92.75	gold quality
hindlimb stylopod muscle	UBERON:0004252	91.97	gold quality
descending thoracic aorta	UBERON:0002345	91.72	gold quality
tendon	UBERON:0000043	91.70	gold quality
right lung	UBERON:0002167	91.46	gold quality
upper leg skin	UBERON:0004262	91.17	gold quality
thoracic aorta	UBERON:0001515	91.08	gold quality
skin of hip	UBERON:0001554	91.07	gold quality
ascending aorta	UBERON:0001496	91.05	gold quality
muscle layer of sigmoid colon	UBERON:0035805	91.01	gold quality
blood	UBERON:0000178	90.94	gold quality
corpus callosum	UBERON:0002336	90.83	gold quality
lower esophagus muscularis layer	UBERON:0035833	90.82	gold quality
lower esophagus	UBERON:0013473	90.81	gold quality
aorta	UBERON:0000947	90.77	gold quality
minor salivary gland	UBERON:0001830	90.68	gold quality
muscle of leg	UBERON:0001383	90.66	gold quality
mucosa of stomach	UBERON:0001199	90.58	gold quality
tibial artery	UBERON:0007610	90.58	gold quality
popliteal artery	UBERON:0002250	90.57	gold quality
sural nerve	UBERON:0015488	90.47	gold quality
tonsil	UBERON:0002372	90.45	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	90.38	gold quality
gastrocnemius	UBERON:0001388	90.34	gold quality
omental fat pad	UBERON:0010414	90.23	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.32
E-GEOD-125970	no	3.13

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

12 targets.

Target	Regulation
ANGPT1
ANGPT2
BLK	Unknown
CD3D	Activation
CD79A
CEL
LYN
MMP1
NOS2
TEK	Activation
TIE1
VCP	Activation

JASPAR motifs

Motif	Name	Family
MA1483.1	ELF2	Ets-related
MA1483.2	ELF2	Ets-related
MA1483.3	ELF2	Ets-related

JASPAR matrix evidence (PMIDs): PMID:20517297

miRNA regulators (miRDB)

126 targeting ELF2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4713-3P	100.00	65.92	505
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-627-3P	99.90	71.42	3316

Literature-anchored findings (GeneRIF, showing 10)

• angiopoietin-1 regulates expression of NERF2 and its own receptor in hypoxic cells. (PMID:11967990)
• NERF/ELF-2 physically interacts with AML1 and mediates opposing effects on AML1-mediated transcription of the B cell-specific blk gene (PMID:14970218)
• These findings indicate that ELF2/NERF promotes VCP transcription and that ELF2/NERF-VCP pathway might be important for cell survival and proliferation under cytokine stress. (PMID:17368566)
• ELF2 transactivates VCP promoter through binding to two motifs, with a predominant contribution of the upstream one. (PMID:18544453)
• Affinity of the CAL PDZ domain for the cystic fibrosis transmembrane conductance regulator (CFTR) C-terminus is much weaker than that of the NHERF1/NHERF2 domains, enabling wild-type CFTR to avoid premature entrapment in the lysosomal pathway. (PMID:18754678)
• Our findings collectively support a potential role of triiodothyronine and its receptor in tumor growth inhibition through regulation of ELF2 (PMID:26968954)
• PCAT7 contributed to the progression of nasopharyngeal carcinoma through regulating miR-134-5p/ELF2 signaling pathway. (PMID:28728844)
• Mutations in eIF2B genes cause vanishing white matter disease due to translation defects. (PMID:29632131)
• Circ_0028007 Aggravates the Malignancy of Nasopharyngeal Carcinoma by Regulating miR-656-3p/ELF2 Axis. (PMID:35239093)
• c-Myc-induced long noncoding RNA MIRE cooperates with hnRNPK to stabilize ELF2 mRNA and promotes clear cell renal cell carcinogenesis. (PMID:37248433)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	elf2b	ENSDARG00000079626
mus_musculus	Elf2	ENSMUSG00000037174
rattus_norvegicus	Elf2	ENSRNOG00000010815

Paralogs (28): ETV1 (ENSG00000006468), ETV7 (ENSG00000010030), SPI1 (ENSG00000066336), ELF4 (ENSG00000102034), ETV2 (ENSG00000105672), ERF (ENSG00000105722), ELK3 (ENSG00000111145), ETV3 (ENSG00000117036), ELF1 (ENSG00000120690), SPDEF (ENSG00000124664), ELK1 (ENSG00000126767), ETS1 (ENSG00000134954), EHF (ENSG00000135373), ELF5 (ENSG00000135374), ETV6 (ENSG00000139083), FLI1 (ENSG00000151702), GABPA (ENSG00000154727), ERG (ENSG00000157554), ETS2 (ENSG00000157557), ELK4 (ENSG00000158711), ELF3 (ENSG00000163435), FEV (ENSG00000163497), SPIC (ENSG00000166211), ETV4 (ENSG00000175832), ETV5 (ENSG00000244405), ETV3L (ENSG00000253831), ERFL (ENSG00000268041), SPIB (ENSG00000269404)

Protein

Protein identifiers

ETS-related transcription factor Elf-2 — Q15723 (reviewed: Q15723)

Alternative names: E74-like factor 2, New ETS-related factor

All UniProt accessions (4): Q15723, B7Z720, D6RGD9, D6RHI1

UniProt curated annotations — full annotation on UniProt →

Function. Isoform 1 transcriptionally activates the LYN and BLK promoters and acts synergistically with RUNX1 to transactivate the BLK promoter. Isoform 2 may function in repression of RUNX1-mediated transactivation.

Subunit / interactions. Interacts with the LIM domains of LMO2. Interacts via its N-terminal region with RUNX1.

Subcellular location. Nucleus.

Tissue specificity. Expressed in all fetal and adult tissues examined. Among fetal tissues, highest levels of expression detected in heart, lung, liver and kidney, and lower levels in brain. Among adult tissues, highest levels of expression detected in heart, placenta, lung, skeletal muscle, spleen, thymus, testis and ovary. Moderate expression in prostate, small intestine, kidney, liver and pancreas, and weak expression in colon, brain and peripheral blood lymphocytes.

Similarity. Belongs to the ETS family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q15723-5	5, NERF-2b	yes
Q15723-1	1, NERF-2, NERF-2a
Q15723-2	2, NERF-1a
Q15723-3	3, NERF-1b
Q15723-4	4

RefSeq proteins (11): NP_001263386, NP_001263387, NP_001263388, NP_001317965, NP_001358253, NP_001358265, NP_001358266, NP_001358267, NP_001358268, NP_006865, NP_973728 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000418	Ets_dom	Domain
IPR022084	TF_Elf_N	Domain
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR046328	ETS_fam	Family

Pfam: PF00178, PF12310

UniProt features (19 total): modified residue 10, splice variant 3, compositionally biased region 2, chain 1, DNA-binding region 1, cross-link 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9IGJ	ELECTRON MICROSCOPY	3.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15723-F1	50.58	0.14

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (11): 372, 376, 430, 494, 521, 536, 107, 182, 185, 191, 363

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8939245	RUNX1 regulates transcription of genes involved in BCR signaling

MSigDB gene sets: 166 (showing top): WENDT_COHESIN_TARGETS_UP, GGGACCA_MIR133A_MIR133B, TGGTGCT_MIR29A_MIR29B_MIR29C, BROWNE_HCMV_INFECTION_6HR_DN, RIZKI_TUMOR_INVASIVENESS_3D_DN, BLALOCK_ALZHEIMERS_DISEASE_UP, AAAGGGA_MIR204_MIR211, KAYO_AGING_MUSCLE_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, ATGTTTC_MIR494, YAGI_AML_WITH_T_9_11_TRANSLOCATION, GOCC_NUCLEAR_BODY, CAGTGTT_MIR141_MIR200A, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, CAGTATT_MIR200B_MIR200C_MIR429

GO Biological Process (5): regulation of transcription by RNA polymerase II (GO:0006357), cell differentiation (GO:0030154), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of DNA-templated transcription (GO:0045893), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription factor activity (GO:0003700), sequence-specific DNA binding (GO:0043565), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (5): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), nuclear body (GO:0016604)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Transcriptional regulation by RUNX1	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	4
DNA-templated transcription	3
cellular anatomical structure	3
transcription by RNA polymerase II	1
cellular developmental process	1
negative regulation of RNA biosynthetic process	1
positive regulation of RNA biosynthetic process	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
DNA binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
nucleoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1008 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ELF2	RUNX1	Q01196	523
ELF2	ZBTB26	Q9HCK0	482
ELF2	KLF6	Q99612	462
ELF2	MYC	P01106	459
ELF2	ETV2	O00321	436
ELF2	CMIP	Q8IY22	429
ELF2	POU2F3	Q9UKI9	422
ELF2	ZNF821	O75541	420
ELF2	ZNF740	Q8NDX6	417
ELF2	KLF8	O95600	406
ELF2	POLR2A	P24928	389
ELF2	PTN	P21246	381
ELF2	ARF3	P16587	375
ELF2	CDKN2A	P42771	374
ELF2	HOXA6	P31267	369

IntAct

75 interactions, top by confidence:

A	B	Type	Score
PSMC3	PSMD9	psi-mi:“MI:0914”(association)	0.940
PRPS1	PRPSAP2	psi-mi:“MI:0914”(association)	0.840
PSMC3	PSMD12	psi-mi:“MI:0914”(association)	0.640
RUNX1	ELF2	psi-mi:“MI:0407”(direct interaction)	0.540
RUNX1	ELF2	psi-mi:“MI:0915”(physical association)	0.540
SPINT2	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
NFATC2IP	ZNHIT1	psi-mi:“MI:0914”(association)	0.530
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
	ELF2	psi-mi:“MI:0915”(physical association)	0.370
DBP	ELF2	psi-mi:“MI:0915”(physical association)	0.370
CCL1	ELF2	psi-mi:“MI:0915”(physical association)	0.370
CCL2	ELF2	psi-mi:“MI:0915”(physical association)	0.370
IL18	ELF2	psi-mi:“MI:0915”(physical association)	0.370
IL23A	ELF2	psi-mi:“MI:0915”(physical association)	0.370
IL36A	ELF2	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (175): ELF2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS), ELF2 (Proximity Label-MS), ELF2 (Proximity Label-MS), ELF2 (Proximity Label-MS), ELF2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS)

ESM2 similar proteins: A0JME2, A2AUY4, D3ZKB9, D4A666, E1B7L7, F1QZ88, F6NSX9, F8VPJ6, P59759, P78364, Q08CM4, Q0IHV2, Q15723, Q2IBE6, Q2IBF7, Q2QLB3, Q3TUF7, Q4G0F8, Q5DTH5, Q5U4Q0, Q5ZIE8, Q5ZM88, Q63HK5, Q641Z1, Q6P4L9, Q6P4R8, Q6PIJ4, Q6ZPK0, Q6ZSZ6, Q6ZU65, Q76L83, Q7ZUK7, Q7ZUV7, Q80WC1, Q8AYC1, Q8BZ32, Q8C966, Q8CGV9, Q8CHP6, Q8NDX5

Diamond homologs: A0A1W2PQ73, A0JN51, A1A4L6, A1YF15, A1YG61, A1YG91, A2D4Z7, A2T737, A2T762, A3FEM2, A4GTP4, A8WFJ9, O00321, O01519, O70132, O70273, O95238, P01105, P10157, P11308, P11536, P13474, P14921, P15036, P15037, P15062, P18755, P18756, P19102, P19419, P20105, P26323, P27577, P28322, P28324, P29773, P29774, P29775, P29776, P32519

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ELF2	“up-regulates quantity by expression”	VCP	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	73
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
431175	NM_001331036.3(ELF2):c.10G>A (p.Ala4Thr)	Likely pathogenic

SpliceAI

3336 predictions. Top by Δscore:

Variant	Effect	Δscore
4:139043072:A:AG	acceptor_gain	1.0000
4:139043072:A:G	acceptor_loss	1.0000
4:139043073:G:GA	acceptor_gain	1.0000
4:139043073:GT:G	acceptor_gain	1.0000
4:139043073:GTGT:G	acceptor_gain	1.0000
4:139044634:TTCA:T	acceptor_loss	1.0000
4:139044636:CAGCT:C	acceptor_loss	1.0000
4:139044637:A:AG	acceptor_gain	1.0000
4:139044637:A:T	acceptor_loss	1.0000
4:139044638:G:GA	acceptor_gain	1.0000
4:139044638:GC:G	acceptor_gain	1.0000
4:139044638:GCT:G	acceptor_gain	1.0000
4:139044638:GCTC:G	acceptor_gain	1.0000
4:139044638:GCTCT:G	acceptor_gain	1.0000
4:139060319:CTTA:C	donor_loss	1.0000
4:139060320:TTACC:T	donor_loss	1.0000
4:139060321:TACCT:T	donor_loss	1.0000
4:139060322:A:C	donor_loss	1.0000
4:139060323:C:CA	donor_loss	1.0000
4:139060670:AGTAT:A	acceptor_gain	1.0000
4:139060671:GTAT:G	acceptor_gain	1.0000
4:139060672:TAT:T	acceptor_gain	1.0000
4:139060673:AT:A	acceptor_gain	1.0000
4:139060675:C:A	acceptor_loss	1.0000
4:139060675:C:CC	acceptor_gain	1.0000
4:139071861:TCTAC:T	donor_loss	1.0000
4:139071862:CTACC:C	donor_loss	1.0000
4:139071864:A:C	donor_loss	1.0000
4:139071865:C:CA	donor_loss	1.0000
4:139072037:CCA:C	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000005012 (4:139168788 A>C), RS1000005855 (4:139124130 A>G), RS1000022125 (4:139072550 G>A), RS10001095 (4:139152885 G>A,C,T), RS1000128786 (4:139075652 C>G), RS1000142850 (4:139123839 T>C), RS1000146697 (4:139123178 G>C,T), RS1000187513 (4:139145318 C>G), RS1000217372 (4:139124913 CTT>C), RS1000232312 (4:139097947 G>A), RS1000257941 (4:139105263 T>C), RS1000258658 (4:139153073 A>T), RS1000264987 (4:139105736 TA>T,TAA), RS1000282402 (4:139150102 G>A), RS1000298155 (4:139092635 C>G)

Disease associations

OMIM: gene MIM:619798 | disease phenotypes: MIM:608088, MIM:614575

GenCC curated gene-disease

Mondo (1): cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (MONDO:0044720)

Orphanet (2): Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (Orphanet:504476), Hereditary sensory and autonomic neuropathy type 1B (Orphanet:139564)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C564296	Neuropathy, Hereditary Sensory And Autonomic, Type I, With Cough And Gastroesophageal Reflux (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects cotreatment, increases abundance, increases expression, increases oxidation, affects expression	2
Ozone	affects cotreatment, increases expression, increases oxidation, increases abundance, affects expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases expression, increases oxidation, increases abundance	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
arsenite	increases methylation	1
sodium arsenite	increases abundance, affects cotreatment, decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
potassium chromate(VI)	decreases expression	1
coumarin	affects phosphorylation	1
methacrylaldehyde	affects cotreatment, increases expression, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
jinfukang	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Acrolein	increases abundance, affects cotreatment, increases expression, increases oxidation	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Caffeine	decreases phosphorylation	1
Calcitriol	increases expression	1
Carbamazepine	affects expression	1
Curcumin	decreases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1G9	SEES3-1V human ELF2, clone1	Embryonic stem cell	Male
CVCL_A1H0	SEES3-1V human ELF2, clone2	Embryonic stem cell	Male
CVCL_A1H1	SEES3-1V human ELF2, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

2 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04153110	Not specified	COMPLETED	Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia
NCT05621200	Not specified	COMPLETED	Transcranial Alternating Current Stimulation (tACS) in Patients With Ataxia